Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
about
What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugsThe experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine usePharmacists' views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study.The structure of the pharmaceutical market in Iran using concentration indices.Make up a missed lesson-New policy to ensure the interchangeability of generic drugs in ChinaQuality use of medicines within universal health coverage: challenges and opportunitiesChallenges and opportunities to use biowaivers to compare generics in China.The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs.Essential medicines are more available than other medicines around the globeMedicines and universal health coverage: challenges and opportunitiesGeneric drugs: Review and experiences from South India.Improving viable low cost generic medication prescription rate in primary care pediatric practice.The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysisPatients perception of community pharmacist in bosnia and herzegovinaEvaluating patients' perceptions regarding generic medicines in Jordan.Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.A Cost Analysis of the Jan Aushadhi Scheme in India.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Knowledge, attitudes, and practices of community pharmacists on generic medicines in Qatar.Generic medicine substitution: a cross-sectional survey of the perception of pharmacists in North-Central, Nigeria.How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?The cyclical behaviour of public and private health expenditure in China.The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians.The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies.Availability, prices and affordability of UN Commission's lifesaving medicines for reproductive and maternal health in Uganda.Knowledge, attitudes and practices of community pharmacists on generic medicines in Palestine: a cross-sectional study.Exploring the Knowledge and Perception of Generic Medicines among Final Year Undergraduate Medical, Pharmacy, and Nursing Students in Sierra Leone: A Comparative Cross-Sectional Approach.Consumers' perception of generic substitution in Iran.A review of promoting access to medicines in China - problems and recommendations.The market dynamics of selective serotonin re-uptake inhibitors: a private sector study in South Africa.Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis CThe Impact of Patent Expiry on Drug Prices: A Systematic Literature ReviewInterrupted time-series analysis of the impact of generic market entry of antineoplastic products in China
P2860
Q26801726-CD764931-3904-451F-A170-C30FBBED557CQ27007695-60AD33B8-623A-4880-B1CD-E08671CC81CEQ30839146-F2DF94C8-FC75-44C1-B548-29AE7B5BADDEQ33764207-3FCF281F-D1F9-42B5-9A24-C5E6A7A1E6D4Q33777981-64605FFB-34E7-416F-93CA-3464E2E7A249Q34151454-D423913A-851C-4B27-9AF0-EB891340C695Q34265204-976F5245-46C2-4A4B-92CE-6AEC2D8072F8Q34373021-A3CC7056-4DBB-437E-8A9B-BA398ECE098EQ35095262-A708C17F-77BA-47FD-AB4C-2E3B20B6E0DCQ35149420-DF825F9A-99A8-4A0A-BC0A-B70FA7E509C3Q35948976-F0261DAA-875A-4520-9EF5-570958850FC0Q36409306-C459368B-B69E-4D8A-B407-D9DB721074D4Q37207470-4421708B-B64E-47BD-81A5-B7BF3565EBACQ37245193-60CFFDCB-27A9-4742-8695-22343EC21D51Q37703344-052E78AC-68A2-4DE1-AC06-98A8F43E70B3Q38263092-997C7543-D82E-41F1-B786-0479E3EBF295Q38622435-0C45D060-5FE2-47D5-B86C-A81158E76BB8Q39072439-B0FF7E35-EDA8-4B25-BF34-28507991B821Q39249776-E81DE418-CADF-4805-9798-CC70DDD58476Q39317365-D10AA434-E2D7-44B7-9280-4C00F9B969DFQ39834356-9ECDBDA8-C91E-4816-B88C-B59C26C4696FQ40122928-9DC75722-B16C-4493-8730-758002A0D194Q40322708-59A5E0D0-6A8F-4440-A9E6-96D3B2948011Q40513945-5949FB6D-C2BB-4B37-B646-F0154251C73FQ42363814-A3256AEA-B0C0-4AD0-A1D3-B2D3460C98FEQ45797141-1C264D3A-966D-474F-B201-B26E2FAB436DQ47146104-516E3DA5-C519-4F25-92EE-A4CFF881B9DBQ47180485-565624A5-D9DB-4D1E-AB88-0A3377086343Q47675163-A2858D73-D856-4043-9F1C-C16924A49B7CQ49842954-E15ABEBC-F1D3-481C-B27D-CCFEE45807FCQ55245356-A2146DCA-63B2-4AFC-B51E-1E9BB4C6B420Q57071808-347DBA18-C912-4B3D-A673-646F137A375FQ57134241-3FD9F438-0606-4C04-BE16-392238114851Q58308717-93913E6C-EFA2-48AE-8731-9096424E0D06
P2860
Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Switching from originator bran ...... ries: how much could be saved?
@en
Switching from originator bran ...... ries: how much could be saved?
@nl
type
label
Switching from originator bran ...... ries: how much could be saved?
@en
Switching from originator bran ...... ries: how much could be saved?
@nl
prefLabel
Switching from originator bran ...... ries: how much could be saved?
@en
Switching from originator bran ...... ries: how much could be saved?
@nl
P2093
P1433
P1476
Switching from originator bran ...... ries: how much could be saved?
@en
P2093
Alexandra Cameron
Aukje K Mantel-Teeuwisse
Hubert G M Leufkens
Richard Ogilvie Laing
P304
P356
10.1016/J.JVAL.2012.04.004
P577
2012-07-11T00:00:00Z